🔴 Neumora Therapeutics is trading 5% down today with no clear catalyst identified

Neumora Therapeutics is trading at $1.54, down 5.21%, with no clear company-specific catalyst identified for August 24, 2026.

• The latest company update located was August 14, 2026, covering second-quarter results and a business update, including a $43.1 million net loss and $116.8 million cash balance.
• Broader trading was mixed, with the Nasdaq Composite down 0.71%, but that does not clearly explain the biotechnology stock’s decline.
• Recent volatility followed earlier sector momentum, leaving the catalyst uncertain.